Seeking Alpha

FDA approves expanded use for Pharmacyclics' Imbruvica

  • The FDA expands the approved use of Imbruvica for the treatment of chronic lymphocytic leukemia patients who have received at least one previous therapy.
  • Press release
  • PCYC +4.3%
From other sites
Comments (2)
  • tsvieps
    , contributor
    Comments (57) | Send Message
     
    This will also become a Frontline therapy for CLL very soon, even though literally it was not yet approved for this. The other still standard therapies are simply destructive to patients compared to Ibrutinib and the soon to be approved CAL 101 from Giliad.

     

    I am taking Ibrutinib for CLL. This was off label until today.
    12 Feb 2014, 07:52 PM Reply Like
  • ike4573
    , contributor
    Comment (1) | Send Message
     
    How were you able to get Imbruvica before FDA approval? I am a CLL patient currently in remission. Ike 4573@gmail.com
    13 Feb 2014, 03:07 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs